美国临床肿瘤学会(ASCO)2011年会报道——消化肿瘤（The American Society of Clinical Oncology (ASCO) 2011 will report digestive cancer）.docVIP

下载本文档

2
0
约1.11万字
约 8页
2017-07-22 发布于河南
举报
版权申诉

美国临床肿瘤学会(ASCO)2011年会报道——消化肿瘤（The American Society of Clinical Oncology (ASCO) 2011 will report digestive cancer）.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

美国临床肿瘤学会(ASCO)2011年会报道——消化肿瘤（The American Society of Clinical Oncology (ASCO) 2011 will report digestive cancer）

美国临床肿瘤学会(ASCO)2011年会报道——消化肿瘤（The American Society of Clinical Oncology (ASCO) 2011 will report digestive cancer） With the increasing incidence of the disease, the study of gastric cancer in European and American countries is increasing. Compared with lung cancer and breast cancer, although the study of gastric cancer published in this years session is a little less, the importance of clinical practice should not be neglected. Important studies in the field of gastric cancer are listed below. 1. patients with high risk of recurrence after GIST were treated with imatinib for 3 years, and the efficacy was 1 years Finland Joensuu researchers report on postoperative high risk of recurrence of gastrointestinal stromal tumor (GIST) patients, imatinib adjuvant treatment for 36 months on relapse free survival (RFS) and overall survival (OS) was better than that for 12 months. (Abstract No. LBA1) For operable GIST patients, 12 months after imatinib adjuvant therapy, RFS is the current standard treatment. The prospective, open, multicenter, randomized phase III study enrolled histologically proven KIT positive GIST patients and compared the efficacy of 12 months and 36 months after imatinib adjuvant therapy. The results showed that the median follow-up of 54 months, imatinib treatment of RFS and OS in 36 months group were significantly longer than 12 months of treatment group (RFS, HR=0.46, P0.0001; OS, HR=0.45, P=0.019), two groups of 5 year RFS rate were 65.6% and 47.9%, OS were 92% and 81.7%. Imatinib is well tolerated and treatment period of 1 years and 3 years respectively were only 2% and 6.1% of patients with recurrent termination of treatment, the two groups during the treatment of non GIST recurrence induced by imatinib discontinuation rates were 25.8% and 12.6%. 2. for first-line treatment of advanced pancreatic cancer, S-1 monotherapy is no less effective than gemcitabine Japanese researchers report Ioka, the first-line treatment of advanced pancreatic cancer, in or